Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.61 |
| ▸ | CCR1 | P32246 | 1/20 | 0.58 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.55 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.55 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117217 | 0.88 | CCR2 (0.59) | CCR2CCR1KCNA5 | |
| SCHEMBL5124336 | 0.82 | ESRRA (0.54) | CCR2KCNA5GPR27 | |
| SCHEMBL3052654 | 0.81 | CCR2 (0.66) | CCR2CCR1 | |
| SCHEMBL5125081 | 0.80 | KCNA5 (0.65) | CCR2CCR1KCNA5 | |
| SCHEMBL5089490 | 0.80 | MAPK1 (0.66) | CCR2CCR1GPR27 | |
| SCHEMBL3137630 | 0.80 | CCR2 (0.56) | CCR2CCR1 | |
| SCHEMBL5114776 | 0.79 | SLC10A6 (0.62) | KCNA5GPR27 | |
| SCHEMBL5095347 | 0.79 | MAPK1 (0.56) | CCR2CCR1GPR27 | |
| SCHEMBL5100683 | 0.79 | KMT2A (0.58) | CCR2CCR1 | |
| SCHEMBL5094269 | 0.79 | CCR2 (0.57) | CCR2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351703-B2 | Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-01 | — | — | US | disclosed |
| EP-1095015-B1 | SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS | AVENTIS PHARMA GMBH (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20050080073-A1 | Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators | AVENTIS PHARMA DEUTSCHLAND GMBH | 2005-04-14 | — | — | US | disclosed |
| US-6809089-B2 | FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISORDERS SUCH AS HIGH BLOOD PRESSURE, ANGINA PECTORIS, CARDIAC INSUFFICIENCY, THROMBOSES OR ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-26 | — | — | US | disclosed |
| US-20030171352-A1 | Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-09-11 | — | — | US | disclosed |
| US-6548547-B1 | Cardiovascular disorders; hypotensive agents, antiasthmatics, cognition activators | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080073-A1 | Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators | GUCY1A1, GUCY1B1, GUCY1A2 | CCR2 1815/4885CCR1 2572/4885KCNA5 1853/4885 |
| US-20030171352-A1 | Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators | GUCY1A1, GUCY1B1, GUCY1B2 | CCR2 1950/4885CCR1 2584/4885KCNA5 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.